A French study (10) focused on PLA2R1-related MGN, comparing high-dose rituximab in the NICE cohort (28 participants, median age 63 years) and GEMRITUX cohort (27 participants, median age 51 years), registered under NCT01508468, NCT02199145, and NCT01897961. This evidence concerns the gene PLA2R1 and idiopathic membranous glomerulonephritis.